U.S. Solid Tumor Testing Market Trend and Forecast 2032

• Posted by BIS Reports June 15, 2022 - Filed in Business - #U.S. Solid Tumor Testing Market  #U.S. Solid Tumor Testing Market report  #U.S. Solid Tumor Testing industry  #U.S. Solid Tumor Testing Market size  #U.S. Solid Tumor Testing Market value  #U.S. Solid Tumor Testing Market growth  #U.S. Solid Tumor Testing Market research  - 1,038 views

  The U.S. solid tumor testing market is progressing rapidly. Significant increases in the research and development activities pertaining to solid tumor testing are underway to develop better testing kits and assays, which are expected to increase due to the rising frequency and efficiency of cancer testing products. 

  The U.S. solid tumor testing market was estimated to be at $9,498.8 million in 2021, which is expected to grow with a CAGR of 6.19% during the forecast period 2022-2032 and reach $18,287.6 million by 2032. The growth in the U.S. solid tumor testing market is expected to be driven by increasing awareness of early tumor diagnosis and tests along with the increasing geriatric population. Furthermore, increasing cancer incidences in the pediatric population.

  

  Source: BIS Research Analysis

  Impact

  •   The presence of major service providers of solid tumor testing in the U.S. has a major impact on the market. For instance, Illumina, Inc. acquired GRAIL which is a cancer detection healthcare company. With this acquisition, Illumina, Inc. can accelerate the adoption of this lifesaving Galleri blood test worldwide which is known to detect 50 different cancer types.
  •   Companies such as QIAGEN partnered with PGDx for molecular cancer testing. With the help of this, laboratories will be able to receive standardized reporting from QIAGEN and receive access to QIAGEN’s QCI Interpret One for rapid next-generation sequencing tests.

   

  Market Segmentation:
   
  Segmentation 1: by Technology
  •    Next-Generation Sequencing
  •    Polymerase Chain Reaction
  •    Fluorescence In-Situ Hybridization
  •    Immunohistochemistry
  •    Liquid Chromatography/Mass Spectrometry
  •    Other Technologies

  Based on technology, the U.S. solid tumor testing market is expected to be dominated by the next-generation sequencing technology. This is due to the high accuracy and efficiency of next-generation sequencing techniques.

  Segmentation 2: by Cancer Type
  •    Breast Cancer
  •    Prostate Cancer
  •    Colorectal Cancer
  •    Lung Cancer
  •    Melanoma
  •    Endometrial Cancer
  •    Lymphoma
  •    Thyroid Cancer
  •    Brain Cancer
  •    Other Cancer Types

  Based on cancer type, the U.S. solid tumor testing market is dominated by breast cancer, owing to an increasing number of patients suffering from breast cancer and also more awareness and better diagnosis of cancer.

  Segmentation 3: by Type of Biomarker
  •    Genetic Biomarker
          o    Molecular Biomarker
          o    Cellular Biomarker
          o    Imaging Biomarker
  •    Protein Biomarker
          o    Predisposition Biomarker
          o    Diagnostic Biomarker
          o    Prognostic Biomarker
          o    Predictive Biomarker

  The genetic biomarkers segment dominates the U.S. solid tumor testing market; however, the protein biomarkers segment shows the largest CAGR of 6.61%. The growth in this segment is mainly due to the growth in research and development, which is leading to the discovery of more biomarkers.

  Segmentation 4: by Application
  •    Clinical 
          o    Diagnostics
          o    Treatment and Monitoring
          o    Screening
          o    Prognosis
  •    Research
          o    Biomarker Discovery 
          o    Personalized Medicine

  The clinical application dominated the application segment. This is because the solid tumor testing market is already well established with many clinical applications. However, the research segment has a higher CAGR of 6.61% as compared to 5.92% for clinical and is expected to grow at a fast pace during the forecast period. Research has increased due to the emergence of personalized medicine.

  Segmentation 5: by End User
  •    Hospitals
  •    Pharmaceutical and Biotechnology Companies
  •    Contract Research Organizations
  •    Academic Research Institutions
  •    Other End Users

  Hospitals dominated the end-user segment. This is due to an increasing number of oncologists playing a key role in the recommendation and data interpretation of solid tumor tests. Due to this, most tests are performed through the hospitals, thereby making it a dominating segment of the market and its growth.

  Segmentation 6: by Region
  •    The Southern U.S.
  •    The Midwest U.S.
  •    The Mid-Atlantic U.S.
  •    The West U.S.
  •    The Southwest U.S.
  •    New England

  The Southern U.S. dominated the regions with a revenue of $2,614.7 in 2021. The high incidence of cancer in a few states like California, Florida, and Texas are the key areas for solid tumor testing market growth.

  Recent Developments in U.S. Solid Tumor Testing Market

  •    In December 2021, Opko Health, Inc. secured FDA approval for its 4Kscore test that is approved for men 45 years or older who haven’t had a prior prostate biopsy or are biopsy negative.
  •    In April 2021, NeoGenomics Laboratories. launched biomarker assist KRAS single gene test. This test is used for advanced or metastatic small cell lung cancer patients.
  •    In November 2020, NeoGenomics Laboratories. started mobile phlebotomy services for liquid biopsy tests. These tests include InVisionFirst-Lung, which is a non-small cell lung liquid biopsy test, and the NeoLab liquid biopsy test, which is used for all solid tumors and hematological cancers.
  •    In February 2020, QIAGEN obtained a CE mark for its therascreen PIK3CA mutation assay. This test can be used to identify breast cancer.

  Key Market Players and Competition Synopsis

  The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

  The top segment players leading the market include solid tumor testing service givers that capture around 70% of the presence in the market, and solid tumor testing product manufacturers contribute around 30% of the presence in the market as of 2021

  Some of the prominent established names in this market are:

  •    Abbott.
  •    ARUP Laboratories
  •    Bio-Rad Laboratories, Inc.
  •    Caris Life Sciences.
  •    F. Hoffmann-La Roche Ltd
  •    Genomic Testing Cooperative
  •    Guardant Health
  •    HTG Molecular Diagnostics, Inc.
  •    Illumina, Inc.
  •    Invitae Corporation
  •    Invivoscribe, Inc.
  •    Laboratory Corporation of America Holdings
  •    NanoString
  •    NeoGenomics Laboratories
  •    Opko Health, Inc.
  •    QIAGEN
  •    Quest Diagnostics Incorporated.
  •    Thermo Fisher Scientific, Inc.
  •    VYANTbio.

  Get Free Sample Report - https://bisresearch.com/requestsample?id=1309type=download

   

  How Can This Report Add Value to an Organization?

  Product/Innovation Strategy: The report considers both the product-based and the service-based companies. Since tumor testing is a service, most of the companies considered are service based. However, technologies such as NGS, PCR, and IHC, that are involved in the testing process of solid tumors are also discussed in detail.

  Growth/Marketing Strategy: The key components in solid tumor testing consist of kits and assays, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis taking into account the main technologies that are used in testing.

  Competitive Strategy: Key players in the U.S. solid tumor testing market were analyzed and profiled in the study, consisting of both product-based and service-based companies as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the U.S. solid tumor testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

   

   

  BIS Related Studies

   

  Global Solid Tumor Testing Market